xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05967507</url>
    </required_header>
    <id_info>
      <org_study_id>OPTIMISE-2-trial</org_study_id>
      <nct_id>NCT05967507</nct_id>
    </id_info>
    <brief_title>Laryngoscopy for Neonatal and Infant Airway Management wIth Supplemental Oxygen at Different Flow Rates (OPTIMISE-2)</brief_title>
    <acronym>OPTIMISE-2</acronym>
    <official_title>Laryngoscopy for Neonatal and Infant Airway Management wIth Supplemental Oxygen at Different Flow Rates (OPTIMISE-2): a Multi-center, Non-inferiority, Prospective Randomized Controlled Trial</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Insel Gruppe AG, University Hospital Bern</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Gaslini Children's Hospital</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>University Hospital, Geneva</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Kantonsspital Aarau</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Luzerner Kantonsspital</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Centre Hospitalier Universitaire Vaudois</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Charite University, Berlin, Germany</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Royal Perth Hospital</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Children's Hospital of Philadelphia</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>The Hospital for Sick Children</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>Insel Gruppe AG, University Hospital Bern</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This study aims to investigate the optimal oxygen flow rate needed during tracheal intubation&#xD;
        with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) using Miller-blade or&#xD;
        Macintosh-blade size No. 0 or No. 1 in the operating room or intensive care unit. The&#xD;
        investigators hypothesize that the difference between low-flow and high-flow supplemental&#xD;
        oxygen is negligible.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Eligible children will be prepared for intubation according to the local SOPs of the&#xD;
        pediatric anesthesia departments. Mandatory monitoring will consist of: SpO2, HR, NIBP.&#xD;
  &#xD;
        Induction of anesthesia: If feasible, all children included in this protocol will be&#xD;
        pre-oxygenated before induction of anesthesia for one minute through face-mask with FiO2 1.0&#xD;
        and flow rates of 6-10L/min. The induction of anesthesia for tracheal intubation will be&#xD;
        performed using a combination of sedative/hypnotic drugs, opioids and non-depolarizing muscle&#xD;
        relaxant.&#xD;
  &#xD;
        The following medications will be mandatory as per protocol:&#xD;
  &#xD;
          -  A neuromuscular blocking agent (NMBA): Rocuronium 0.5-1 mg/kg, Cis-Atracurium 0.2-0.5&#xD;
             mg/kg, Atracurium 0,5 mg/kg, Vecuronium 0.1 mg/kg, Mivacurium 0.2 - 0.3 mg/kg or&#xD;
             Succinylcholine 2 mg/kg.&#xD;
  &#xD;
          -  One or more of the following hypnotic agents (Thiopentone 4-7 mg/kg, Ketamine 0.5-2&#xD;
             mg/kg, Propofol 1-4 mg/kg, Midazolam 0.5-1 mg/kg, Sevoflurane up to 8%).&#xD;
  &#xD;
          -  An opioid drug and anticholinergic can be chosen and administered at the discretion of&#xD;
             the anesthetist in charge.&#xD;
  &#xD;
        Before intubation: After induction of anesthesia and the administration of a NMBA, bag-mask&#xD;
        ventilation with FiO2 1.0 (flow rates of 6-10 L/min) will be performed for 60 seconds until&#xD;
        apnea sets in. After induction all patients will be paralyzed to facilitate airway&#xD;
        management. Full neuromuscular blockade will be assessed by train-of-four (TOF) monitoring.&#xD;
        Thereafter oxygen administration, laryngoscopy and tracheal intubation are performed.&#xD;
  &#xD;
        During intubation: The administration of oxygen during intubation is mandatory for every&#xD;
        study participant and is randomized as follows:&#xD;
  &#xD;
        Low-flow Oxygen Group: For orally intubated children, the administration of low-flow oxygen&#xD;
        (0.2 L/kg/min FiO2 1.0) takes place via conventional nasal cannula (Intersurgical, Wokingham,&#xD;
        UK). For nasally intubated children, the administration of low-flow oxygen (0.2 L/kg/min FiO2&#xD;
        1.0) takes place via a nasal oxygen sponge cannula (Vygon, Ecouen, France) adapted to the&#xD;
        dimension of nare. After administration of low-flow oxygen laryngoscopy and tracheal&#xD;
        intubation are performed.&#xD;
  &#xD;
        High-Flow Oxygen Group (control-group): For all orally intubated children, the administration&#xD;
        of high-flow oxygen (2 L/kg/min FiO2 1.0) takes place via nasal cannula with the Optiflow&#xD;
        (Fisher &amp; Paykel Healthcare, Auckland, New Zealand). For nasally intubated children, the&#xD;
        administration of low-flow oxygen (2 L/kg/min FiO2 1.0) takes place via the anaesthesia&#xD;
        circuit through the tracheal tube placed in the nose. After administration of high-flow&#xD;
        oxygen laryngoscopy and tracheal intubation are performed.&#xD;
  &#xD;
        For a premature neonate &lt; 1kg an uncuffed tube ID 2.5 will be used. For premature babies and&#xD;
        newborn between 1kg and 3.0 kg an uncuffed tube ID 3.0 will be used. For babies &gt; 3.0 kg - 8&#xD;
        months a cuffed tube ID 3.0 or an uncuffed tube 3.5 will be used. For infants 8 months - 12&#xD;
        months a cuffed tube ID 3.5 or an uncuffed tube 4.0 will be used. Based on the group of&#xD;
        randomization, the child will receive supplemental oxygen low-flow via a conventional nasal&#xD;
        cannula vs high-flow with the Optiflow (Fisher &amp; Paykel Healthcare, Auckland, New Zealand).&#xD;
  &#xD;
        Miller-blade or Macintosh-blade size No. 0 will be used for children &lt; 1 kg. In cases of&#xD;
        unexpected difficult intubation, the difficult airway algorithm (18) will be followed. After&#xD;
        the first unsuccessful intubation attempt with the randomized flowrate, the investigators&#xD;
        encourage to perform a second attempt with the same rate but based on the clinical judgment&#xD;
        the intubating physician can proceed to an attempt with the same technique, or change the&#xD;
        flow rate, blade size or the type of laryngoscope. A maximum of 4 intubation attempts in&#xD;
        total will be performed. The last intubation attempt must be performed by the most&#xD;
        experienced physician in the room. Additional devices like stylet, bougie, etc., can be used&#xD;
        at any stage of the intubation process. If the intubation remains unsuccessful the difficult&#xD;
        airway algorithm will be followed (Appendix) and a supraglottic airway - SGA will be&#xD;
        inserted.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 2023</start_date>
    <completion_date type="Anticipated">December 2025</completion_date>
    <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Prevention</primary_purpose>
      <masking>Single (Participant)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>First attempt success rate</measure>
      <time_frame>15 minutes</time_frame>
      <description>The primary study outcome is to evaluate the first attempt success rate of oral and nasal tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with supplemental oxygen with low-flow vs high flow among neonates and infants up to 52 weeks postconceptual age. A successful tracheal intubation (ETI) attempt is defined as successful placement of a tracheal tube in the trachea, confirmed by visualization of the tube passing the vocal cords, a waveform capnography suggesting correct ETT placement and auscultation of breath sounds in the lungs.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Occurrence of severe desaturation</measure>
      <time_frame>15 minutes</time_frame>
      <description>Occurrence and duration of moderate and severe desaturation (SpO2 &lt; 90% and SpO2 &lt; 80%), with or without bradycardia, during intubation.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Overall number of intubation attempts</measure>
      <time_frame>15 minutes</time_frame>
      <description>Overall number of intubation attempts</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>First attempt success rate of tracheal intubation</measure>
      <time_frame>15 Minutes</time_frame>
      <description>First attempt success rate of tracheal intubation</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Time required for intubation</measure>
      <time_frame>5 minutes</time_frame>
      <description>Time required for intubation (in seconds, defined from the first introduction of laryngoscope between the lips till successful lung ventilation defined as positive capnography)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>First EtCO2 after successful intubation</measure>
      <time_frame>10 minutes</time_frame>
      <description>Value in mmHg or kPa of the first reliable etCO2 reading after successful intubation</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Cormack-Lehane score</measure>
      <time_frame>5 minutes</time_frame>
      <description>Cormack-Lehane score at any attempt of laryngoscopy</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The need for additional devices</measure>
      <time_frame>5 minutes</time_frame>
      <description>The need for additional devices used at any step of intubation</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Respiratory complications</measure>
      <time_frame>24 hours</time_frame>
      <description>Respiratory complications or complications of airway management within the first 24 hours, such as airway injury, cardiopulmonary resuscitation, bleeding, aspiration of gastric contents, post-extubation stridor, laryngospasm, bronchospasm, need for High Flow Nasal Oxygen (if not preoperatively on oxygen), need for low flow nasal oxygen (if not preoperatively on oxygen) or need for re-intubation will be recorded. Respiratory complications are defined as the need for re-intubation after being extubated, persistent stridor (even if oxygen is not required), respiratory failure, the occurrence of pneumothorax or the need for any additional diagnostic examination following respiratory problems (i.e., bronchoscopy, radiology).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Duration of severe desaturation</measure>
      <time_frame>15 minutes</time_frame>
      <description>Duration of moderate and severe desaturation (SpO2 &lt; 80%), with or without bradycardia, during intubation.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Percentage of Glottic Opening (POGO) score</measure>
      <time_frame>5 minutes</time_frame>
      <description>Percentage of Glottic Opening (POGO) score at any attempt of laryngoscopy, (0-100%). 100% best glottic opening</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">1132</enrollment>
    <condition>Airway Management</condition>
    <arm_group>
      <arm_group_label>Intervention group</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>0.2 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with conventional nasal cannula during tracheal intubation performed with the C-MAC videolaryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Control group</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>2 L/kg/min FiO2 1.0 high-flow nasal supplemental oxygen with the Optiflow (Fisher &amp; Paykel Healthcare, Auckland, New Zealand) during tracheal intubation performed with the C-MAC videolaryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.</description>
    </arm_group>
    <intervention>
      <intervention_type>Device</intervention_type>
      <intervention_name>Low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope</intervention_name>
      <description>0.2 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.</description>
      <arm_group_label>Intervention group</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Device</intervention_type>
      <intervention_name>High-flow nasal supplemental oxygen (Fisher &amp; Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope</intervention_name>
      <description>2 L/kg/min FiO2 1.0 high-flow nasal supplemental oxygen (Fisher &amp; Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.</description>
      <arm_group_label>Control group</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Pediatric patients requiring oral or nasal tracheal intubation for elective,&#xD;
               semi-elective, or urgent surgical and non-surgical indications.&#xD;
  &#xD;
            -  Neonates and infants up to 52 weeks postconceptual age, with legal guardians providing&#xD;
               written informed consent before the intervention&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Prediction of difficult intubation upon physical examination or previous history of&#xD;
               difficult intubation, mandating a technique different than direct laryngoscopy to&#xD;
               secure the airway;&#xD;
  &#xD;
            -  Congenital heart disease demanding FiO2 &lt; 1.0&#xD;
  &#xD;
            -  Cardiopulmonary collapse requiring advanced life support&#xD;
  &#xD;
            -  Intubation for emergency surgical and non-surgical indications.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>N/A</minimum_age>
      <maximum_age>52 Weeks</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Thomas Riva, MD</last_name>
      <role>Study Chair</role>
      <affiliation>University of Bern</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Alexander Fuchs, MD</last_name>
      <phone>+41 31 632 52 01</phone>
      <email>alexander.fuchs@insel.ch</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Thomas Riva, MD</last_name>
      <phone>+41 31 632 17 09</phone>
      <email>thomasriva@me.com</email>
    </overall_contact_backup>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 19, 2023</study_first_submitted>
    <study_first_submitted_qc>July 27, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 1, 2023</study_first_posted>
    <last_update_submitted>July 31, 2023</last_update_submitted>
    <last_update_submitted_qc>July 31, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 2, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05967507
  org study id: OPTIMISE-2-trial
  nct id: NCT05967507
  lead sponsor: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  This study aims to investigate the optimal oxygen flow rate needed during tracheal intubation
        with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) using Miller-blade or
        Macintosh-blade size No. 0 or No. 1 in the operating room or intensive care unit. The
        investigators hypothesize that the difference between low-flow and high-flow supplemental
        oxygen is negligible.
  Eligible children will be prepared for intubation according to the local SOPs of the
        pediatric anesthesia departments. Mandatory monitoring will consist of: SpO2, HR, NIBP.
  
        Induction of anesthesia: If feasible, all children included in this protocol will be
        pre-oxygenated before induction of anesthesia for one minute through face-mask with FiO2 1.0
        and flow rates of 6-10L/min. The induction of anesthesia for tracheal intubation will be
        performed using a combination of sedative/hypnotic drugs, opioids and non-depolarizing muscle
        relaxant.
  
        The following medications will be mandatory as per protocol:
  
          -  A neuromuscular blocking agent (NMBA): Rocuronium 0.5-1 mg/kg, Cis-Atracurium 0.2-0.5
             mg/kg, Atracurium 0,5 mg/kg, Vecuronium 0.1 mg/kg, Mivacurium 0.2 - 0.3 mg/kg or
             Succinylcholine 2 mg/kg.
  
          -  One or more of the following hypnotic agents (Thiopentone 4-7 mg/kg, Ketamine 0.5-2
             mg/kg, Propofol 1-4 mg/kg, Midazolam 0.5-1 mg/kg, Sevoflurane up to 8%).
  
          -  An opioid drug and anticholinergic can be chosen and administered at the discretion of
             the anesthetist in charge.
  
        Before intubation: After induction of anesthesia and the administration of a NMBA, bag-mask
        ventilation with FiO2 1.0 (flow rates of 6-10 L/min) will be performed for 60 seconds until
        apnea sets in. After induction all patients will be paralyzed to facilitate airway
        management. Full neuromuscular blockade will be assessed by train-of-four (TOF) monitoring.
        Thereafter oxygen administration, laryngoscopy and tracheal intubation are performed.
  
        During intubation: The administration of oxygen during intubation is mandatory for every
        study participant and is randomized as follows:
  
        Low-flow Oxygen Group: For orally intubated children, the administration of low-flow oxygen
        (0.2 L/kg/min FiO2 1.0) takes place via conventional nasal cannula (Intersurgical, Wokingham,
        UK). For nasally intubated children, the administration of low-flow oxygen (0.2 L/kg/min FiO2
        1.0) takes place via a nasal oxygen sponge cannula (Vygon, Ecouen, France) adapted to the
        dimension of nare. After administration of low-flow oxygen laryngoscopy and tracheal
        intubation are performed.
  
        High-Flow Oxygen Group (control-group): For all orally intubated children, the administration
        of high-flow oxygen (2 L/kg/min FiO2 1.0) takes place via nasal cannula with the Optiflow
        (Fisher & Paykel Healthcare, Auckland, New Zealand). For nasally intubated children, the
        administration of low-flow oxygen (2 L/kg/min FiO2 1.0) takes place via the anaesthesia
        circuit through the tracheal tube placed in the nose. After administration of high-flow
        oxygen laryngoscopy and tracheal intubation are performed.
  
        For a premature neonate < 1kg an uncuffed tube ID 2.5 will be used. For premature babies and
        newborn between 1kg and 3.0 kg an uncuffed tube ID 3.0 will be used. For babies > 3.0 kg - 8
        months a cuffed tube ID 3.0 or an uncuffed tube 3.5 will be used. For infants 8 months - 12
        months a cuffed tube ID 3.5 or an uncuffed tube 4.0 will be used. Based on the group of
        randomization, the child will receive supplemental oxygen low-flow via a conventional nasal
        cannula vs high-flow with the Optiflow (Fisher & Paykel Healthcare, Auckland, New Zealand).
  
        Miller-blade or Macintosh-blade size No. 0 will be used for children < 1 kg. In cases of
        unexpected difficult intubation, the difficult airway algorithm (18) will be followed. After
        the first unsuccessful intubation attempt with the randomized flowrate, the investigators
        encourage to perform a second attempt with the same rate but based on the clinical judgment
        the intubating physician can proceed to an attempt with the same technique, or change the
        flow rate, blade size or the type of laryngoscope. A maximum of 4 intubation attempts in
        total will be performed. The last intubation attempt must be performed by the most
        experienced physician in the room. Additional devices like stylet, bougie, etc., can be used
        at any stage of the intubation process. If the intubation remains unsuccessful the difficult
        airway algorithm will be followed (Appendix) and a supraglottic airway - SGA will be
        inserted.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Prevention
  masking: Single (Participant)
  measure: First attempt success rate
  time frame: 15 minutes
  description: The primary study outcome is to evaluate the first attempt success rate of oral and nasal tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with supplemental oxygen with low-flow vs high flow among neonates and infants up to 52 weeks postconceptual age. A successful tracheal intubation (ETI) attempt is defined as successful placement of a tracheal tube in the trachea, confirmed by visualization of the tube passing the vocal cords, a waveform capnography suggesting correct ETT placement and auscultation of breath sounds in the lungs.
  measure: Occurrence of severe desaturation
  time frame: 15 minutes
  description: Occurrence and duration of moderate and severe desaturation (SpO2 < 90% and SpO2 < 80%), with or without bradycardia, during intubation.
  measure: Overall number of intubation attempts
  time frame: 15 minutes
  description: Overall number of intubation attempts
  measure: First attempt success rate of tracheal intubation
  time frame: 15 Minutes
  description: First attempt success rate of tracheal intubation
  measure: Time required for intubation
  time frame: 5 minutes
  description: Time required for intubation (in seconds, defined from the first introduction of laryngoscope between the lips till successful lung ventilation defined as positive capnography)
  measure: First EtCO2 after successful intubation
  time frame: 10 minutes
  description: Value in mmHg or kPa of the first reliable etCO2 reading after successful intubation
  measure: Cormack-Lehane score
  time frame: 5 minutes
  description: Cormack-Lehane score at any attempt of laryngoscopy
  measure: The need for additional devices
  time frame: 5 minutes
  description: The need for additional devices used at any step of intubation
  measure: Respiratory complications
  time frame: 24 hours
  description: Respiratory complications or complications of airway management within the first 24 hours, such as airway injury, cardiopulmonary resuscitation, bleeding, aspiration of gastric contents, post-extubation stridor, laryngospasm, bronchospasm, need for High Flow Nasal Oxygen (if not preoperatively on oxygen), need for low flow nasal oxygen (if not preoperatively on oxygen) or need for re-intubation will be recorded. Respiratory complications are defined as the need for re-intubation after being extubated, persistent stridor (even if oxygen is not required), respiratory failure, the occurrence of pneumothorax or the need for any additional diagnostic examination following respiratory problems (i.e., bronchoscopy, radiology).
  measure: Duration of severe desaturation
  time frame: 15 minutes
  description: Duration of moderate and severe desaturation (SpO2 < 80%), with or without bradycardia, during intubation.
  measure: Percentage of Glottic Opening (POGO) score
  time frame: 5 minutes
  description: Percentage of Glottic Opening (POGO) score at any attempt of laryngoscopy, (0-100%). 100% best glottic opening
  arm group label: Intervention group
  arm group type: Experimental
  description: 0.2 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with conventional nasal cannula during tracheal intubation performed with the C-MAC videolaryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
  arm group label: Control group
  arm group type: Active Comparator
  description: 2 L/kg/min FiO2 1.0 high-flow nasal supplemental oxygen with the Optiflow (Fisher & Paykel Healthcare, Auckland, New Zealand) during tracheal intubation performed with the C-MAC videolaryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
  intervention type: Device
  intervention name: Low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope
  description: 0.2 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
  arm group label: Intervention group
  intervention type: Device
  intervention name: High-flow nasal supplemental oxygen (Fisher & Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope
  description: 2 L/kg/min FiO2 1.0 high-flow nasal supplemental oxygen (Fisher & Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
  arm group label: Control group
  criteria: 
  gender: All
  minimum age: N/A
  maximum age: 52 Weeks
  healthy volunteers: No
  last name: Thomas Riva, MD
  role: Study Chair
  affiliation: University of Bern
  last name: Alexander Fuchs, MD
  phone: +41 31 632 52 01
  email: alexander.fuchs@insel.ch
  last name: Thomas Riva, MD
  phone: +41 31 632 17 09
  email: thomasriva@me.com
  responsible party type: Sponsor
  sharing ipd: No